Venous Thromboembolism | Landscape & Forecast | Disease Landscape & Forecast

Publish date: October 2018

Login to access report

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The availability of non-vitamin K antagonist oral anticoagulants (NOACs) for the treatment and secondary prophylaxis of VTE is addressing the need for more-convenient alternatives to current standards of care, and these agents will drive market growth during the forecast period. However, considerable areas of unmet need exist within the VTE space, such as primary prophylaxis of VTE in acute medically ill patients and management of VTE treatment and risk in cancer patients. The ongoing label expansion program for NOACs and the anticipated launch of new therapies such as IONIS-FXIRx offer potential solutions to these unmet needs.

Questions Answered:

  • How do the different VTE subpopulations contribute to the overall VTE market landscape? What will be the key drivers and deterrents for the VTE market during the 2017-2027 forecast period?
  • How will uptake of newer agents in the market impact current market-leading therapies? Which agents will be the most successful and why?
  • What do thought leaders think of the label expansion programs for NOACs? How do physicians perceive betrixaban, a new NOAC on the market, for managing medically ill patients?
  • Which patient subpopulations have the greatest unmet need and commercial potential? Which drugs under development will fulfill these unmet needs?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with thought leaders in the field.

Epidemiology: Number of DVT events; number of PE events; number of hospitalization events (orthopedic surgery, major non-orthopedic surgery, nonsurgical) eligible for VTE acute primary prophylaxis; number of prevalent cases of cancer patients eligible for VTE primary prophylaxis.

Population segments in market forecast: Primary prophylaxis indications (major orthopedic surgery, non-orthopedic surgery, nonsurgical patients, cancer patients eligible for prophylaxis); acute DVT treatment and secondary prophylaxis; acute PE treatment and secondary prophylaxis.

Emerging therapies: Phase II: 3 drugs; Phase III: 3 drugs. Coverage of select preclinical and Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • October 2018
      • August 2018
      • June 2018
      • February 2018
      • December 2017
      • August 2017
      • June 2017
      • March 2017
    • Market Outlook
      • Key Findings
        • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Venous Thromboembolism?
        • What Factors Are Constraining the Market for Venous Thromboembolism?
      • Drug-Class-Specific Trends
        • Oral Factor Xa Inhibitors
        • Direct Thrombin Inhibitors
        • Vitamin K Antagonists
        • Factor XI Inhibitors
        • Heparins and Heparinoids
        • Thrombolytics
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Assumptions
      • Market Forecast Dashboard
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
      • Vascular Endothelial Injury
      • Venous Stasis
      • Hypercoagulability: Prothrombotic State
      • The Coagulation Process
        • The Cascade Model
        • The Cell-Based Model
      • VTE Risk Factors
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Events of Venous Thromboembolism
        • Diagnosed Events of VTE Acute Prophylaxis
        • Diagnosed Events of VTE Prophylaxis in Cancer
        • Drug-Treated Events of VTE
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Vitamin K Antagonists
        • Heparins and Heparinoids
        • Indirect Factor Xa Inhibitors
        • Oral Factor Xa Inhibitors
        • Direct Thrombin Inhibitors
        • Thrombolytics
      • Medical Practice
        • Overview
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Venous Thromboembolism
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Venous Thromboembolism
        • Oral Factor Xa Inhibitors
        • Factor XI Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Venous Thromboembolism
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Venous Thromboembolism Bibliography

Author(s): Shreya Saxena, MBA; Ema Rodrigues, DSc, MPH

Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.

Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degree (MPH, ) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.